Shareholders Approve Reverse Stock Split to Maintain Nasdaq Listing
APRE sits 42% above its 52-week low of $0.548 on light trading volume (0.2× avg).
Summary
Aprea Therapeutics shareholders approved a reverse stock split, empowering the Board to implement it to maintain the company's Nasdaq listing.
Key Events · Corporate Governance and Compliance · APRE
-
Reverse Stock Split Approved
Shareholders approved an amendment to the company's charter, authorizing the Board of Directors to effect a reverse stock split at a ratio between 1-for-3 and 1-for-8. The exact ratio and timing will be determined by the Board.
-
Director Elections
Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D. were re-elected as Class I directors to serve until the 2029 Annual Meeting.
-
Auditor Ratification
The appointment of EisnerAmper LLP as the independent registered public accounting firm for the 2026 fiscal year was ratified by stockholders.
Analysis · APRE · Life Sciences
Shareholders have approved a reverse stock split, granting the Board discretion to implement a ratio between 1-for-3 and 1-for-8. This action is critical for Aprea Therapeutics to address its low stock price and regain compliance with Nasdaq's minimum bid price requirement, thereby avoiding potential delisting. While reverse splits are often viewed negatively, this approval prevents a more severe outcome for the micro-cap company.
At the time of this filing, APRE was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $0.55 to $2.22. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.